Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

[1]  T. Heise,et al.  Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile compared with insulin glargine , 2012 .

[2]  T. Christensen,et al.  The impact of non-severe hypoglycemic events on work productivity and diabetes management. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[3]  P. Home,et al.  Hypoglycemia rates with basal insulin analogs. , 2011, Diabetes technology & therapeutics.

[4]  J. DeVries,et al.  Insulin Degludec in Type 1 Diabetes , 2011, Diabetes Care.

[5]  V. Basevi.  Standards of Medical Care in Diabetes—2011 , 2011, Diabetes Care.

[6]  S. Amiel,et al.  Hypoglycemia Unawareness Is Associated With Reduced Adherence to Therapeutic Decisions in Patients With Type 1 Diabetes , 2009, Diabetes Care.

[7]  B. Zinman,et al.  Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.

[8]  B. Frier.  How hypoglycaemia can affect the life of a person with diabetes , 2008, Diabetes/metabolism research and reviews.

[9]  T. Pieber,et al.  Refining basal insulin therapy: what have we learned in the age of analogues? , 2007, Diabetes/metabolism research and reviews.

[10]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[11]  R. Davis,et al.  Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes , 2005, Current medical research and opinion.

[12]  George Scott,et al.  Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. , 2004, Journal of immunological methods.

[13]  A. Hamann,et al.  A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. , 2003, Diabetes care.

[14]  A. Novials,et al.  The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemias in patients with type 1 and type 2 diabetes but is not better than frequent capillary glucose measurements for improving metabolic control. , 2003, Diabetes care.

[15]  P. Raskin,et al.  Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. , 2002, Diabetes care.

[16]  N. Rege,et al.  ICH Harmonised Tripartite Guideline: guideline for good clinical practice. , 2001, Journal of postgraduate medicine.

[17]  Helsinki,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, Journal of the American Medical Association (JAMA).

[18]  I. Macdonald,et al.  Well-Being, Cerebral Function, and Physical Fatigue After Nocturnal Hypoglycemia in IDDM , 1998, Diabetes Care.

[19]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[20]  P. Cryer,et al.  Induction of Hypoglycemia Unawareness by Asymptomatic Nocturnal Hypoglycemia , 1993, Diabetes.

[21]  B. Gandevia,et al.  DECLARATION OF HELSINKI. , 1964, The Medical journal of Australia.

[22]  Sue Eckstein.  Ethical principles for medical research involving human subjects , 2003 .